IQVIA (NYSE:IQV) Given New $235.00 Price Target at Barclays

IQVIA (NYSE:IQV) had its price objective decreased by stock analysts at Barclays from $255.00 to $235.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 17.18% from the stock’s current price.

A number of other brokerages also recently commented on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $254.53.

IQVIA Price Performance

IQV traded down $0.82 during trading hours on Monday, hitting $200.54. The company’s stock had a trading volume of 608,893 shares, compared to its average volume of 1,350,223. The stock has a market cap of $36.40 billion, a price-to-earnings ratio of 26.31, a P/E/G ratio of 2.15 and a beta of 1.48. The business’s 50-day moving average price is $200.41 and its 200-day moving average price is $220.32. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73.

Institutional Trading of IQVIA

Large investors have recently bought and sold shares of the stock. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the 3rd quarter valued at $28,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth $33,000. Avior Wealth Management LLC raised its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Finally, Assetmark Inc. lifted its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.